Key result
Rivaroxaban is at least as effective as warfarin for preventing stroke or systemic embolism in non-valvular atrial fibrillation, with a lower risk of fatal bleeding and intracranial hemorrhage.
Why the study?
Does rivaroxaban reduce stroke or systemic embolism in patients with non-valvular atrial fibrillation compared to warfarin?
Does rivaroxaban reduce stroke or systemic embolism in patients with non-valvular atrial fibrillation compared to warfarin?
Rivaroxaban is an effective and safe alternative to warfarin for stroke prevention in non-valvular atrial fibrillation, offering the convenience of once-daily dosing without routine monitoring.
Answers are grounded in this paper and cite their sources.
Supports rivaroxaban preference in non-valvular AF; leaves open need for updated head-to-head comparisons.
In the majority of patients with non-valvular atrial fibrillation (AF) anticoagulation is required to reduce the risk of stroke. Although vitamin K antagonists effectively reduce the risk of stroke, they have many disadvantages that limit their use. Rivaroxaban is a new once-daily oral anticoagulant that overcomes some of these limitations (i.e., no monitoring of anticoagulant effect required and fixed doses can be prescribed). In recent AF studies, rivaroxaban was reported to be at least as effective as warfarin for the prevention of stroke or systemic embolism but with a lesser risk of fatal bleeding and intracranial hemorrhage. More recent data have confirmed the beneficial effects of rivaroxaban, as originally described, and irrespective of the history of previous stroke, heart failure, myocardial infarction, diabetes, moderate renal dysfunction or age. In the present review the authors discuss current evidence regarding the efficacy and safety of rivaroxaban in patients with non-valvular AF.
No takes yet. Share an insight, caveat, or question.
Martínez‐Rubio et al. (2014) conducted a review in Non-valvular atrial fibrillation. Rivaroxaban vs. Warfarin was evaluated on Stroke or systemic embolism. Rivaroxaban is at least as effective as warfarin for preventing stroke or systemic embolism in non-valvular atrial fibrillation, with a lower risk of fatal bleeding and intracranial hemorrhage.
Synapse has enriched 10 related papers. Consider them for comparative context: